Claims for Patent: 7,960,111

Summary for Patent: 7,960,111

Title:	NALP7-based diagnosis of female reproductive conditions
Abstract:	Methods, reagents and kits are described for the diagnosis of a female reproductive condition, based on the detection of an alteration in a NALP7-encoding nucleic acid or a NALP7 polypeptide, relative to a corresponding wild-type NALP7-encoding nucleic acid or NALP7 polypeptide.
Inventor(s):	Slim; Rima (Montreal, CA)
Assignee:	The Royal Institution for the Advancement of Learning/McGill University (Montreal, CA)
Application Number:	11/997,678
Patent Claims:	1. A method for diagnosing a predisposition for molar pregnancy in a human female subject, the method comprising detecting an alteration in the sequence of a NALP7 gene or the sequence of its mRNA or encoded polypeptide in a tissue sample from said subject relative to the sequence of a wild-type NALP7 gene or the sequence of its mRNA or encoded polypeptide, wherein said alteration is: a) a substitution of G with A at the splice donor site at the boundary of exon 3 and intron 3 (IVS3+1G>A); b) a substitution of G with A at the splice donor site at the boundary of exon 7 and intron 7 (IVS7+1G>A); c) a substitution of C with T corresponding to the first position of the codon for Arg 693 of the NALP7 polypeptide, resulting in a Arg to Trp substitution; d) a substitution of G with A corresponding to the second position of the codon for Cys 84 of the NALP7 polypeptide, resulting in a Cys to Tyr substitution; e) a substitution of G with A corresponding to the second position of the codon for Cys 399 of the NALP7 polypeptide, resulting in a Cys to Tyr substitution; f) a substitution of G with C corresponding to the third position of the codon for Lys 379 of the NALP7 polypeptide, resulting in a Lys to Asn substitution; g) a substitution of G with T corresponding to the first position of the codon for Glu 99 of the NALP7 polypeptide, resulting in a substitution for a stop codon; and/or h) a substitution of A with T corresponding to the second position of the codon for Asp 657 of the NALP7 polypeptide, resulting in a Asp to Val substitution wherein if the NALP7 polypeptide is used for detecting said alteration, said alteration is detected by sequencing of the NALP7 polypeptide, and wherein said alteration indicates that the subject has a predisposition for molar pregnancy. 2. The method of claim 1, wherein said substitution of G with A at the splice donor site at the boundary of exon 3 and intron 3 (IVS3+1G>A) is associated with a loss of a cleavage site for the restriction endonuclease BstN1in the NALP7 gene. 3. The method of claim 1, further comprising amplification of a nucleic acid sequence suspected of comprising the alteration in the sample prior to the detection of the alteration. 4. The method of claim 1, wherein detection of the alteration in the sequence of the NALP7 gene or the sequence of its mRNA is performed using a method selected from: a) sequencing of the NALP7 nucleic acid sequence; b) hybridization of a nucleic acid probe capable of specifically hybridizing to a NALP7 nucleic acid sequence comprising the alteration and not to a corresponding wild-type NALP7 nucleic acid sequence; c) restriction fragment length polymorphism analysis (RFLP); d) amplified fragment length polymorphism PCR (AFLP-PCR); and/or e) amplification of a nucleic acid fragment comprising a NALP7 nucleic acid sequence using a primer specific for the alteration, wherein the primer produces an amplified product if the alteration is present and does not produce the same amplified product when a corresponding wild-type NALP7 nucleic acid sequence is used as a template for amplification. 5. The method of claim 4, wherein said primer comprises a nucleotide sequence selected from SEQ ID NOs: 6-42. 6. The method of claim 1, further comprising determining cytokine release of an immune cell of said subject, wherein a decrease in cytokine release relative to a control level of cytokine release is further indicative that the subject suffers from or has a predisposition for the reproductive condition. 7. The method of claim 6, wherein the control level is selected from an established standard and a level of cytokine release of an immune cell comprising a wild-type NALP7 nucleic acid. 8. The method of claim 6, wherein the immune cell is a lymphocyte or monocyte. 9. The method of claim 6, wherein the immune cell is a peripheral blood mononuclear cell (PBMC). 10. The method of claim 6, wherein the cytokine is selected from interleukin-1.beta. (IL-1 .beta.) and TNF alpha (TNF.alpha.).

Details for Patent 7,960,111

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2025-08-03
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2025-08-03
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2025-08-03